Cancer Research UK logo.
SearchDonate
  • Search

A trial of temozolomide for children with neuroblastoma that has come back after treatment (NAG 2003 02)

Overview

Cancer types:

Children's cancers, Neuroblastoma

Status:

Results

Phase:

Phase 2

Details

This trial was looking at the chemotherapy drug temozolomide for children with neuroblastoma.

is a rare type of cancer that affects young children. Doctors usually treat it with chemotherapy, surgery and sometimes radiotherapy. But sometimes the treatment doesn’t work very well, or the cancer comes back after treatment (recurs). If this happens it is more difficult to treat.

Temozolomide is a chemotherapy drug that doctors use to treat some forms of brain tumour in adults (such as glioma). The researchers think temozolomide may be useful for treating children with neuroblastoma.

The aim of this trial was to see how well temozolomide worked for children with neuroblastoma that had not responded to treatment, or that had come back after treatment.

Recruitment start: 1 March 2003

Recruitment end: 30 June 2004

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Julia Chisholm

Professor Andy Pearson

Supported by

Children's Cancer and Leukaemia Group (CCLG)

NIHR Clinical Research Network: Cancer

Last reviewed: 21 Feb 2012

CRUK internal database number: 277

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.